ALX Oncology

Focus: ALX Oncology is an immuno-oncology focused biotech company headquartered in South San Francisco, developing novel immunotherapies for solid tumors. The company operates at early clinical stage with a pipeline concentrated in Phase 1/2 development.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About ALX Oncology

AI assessmentNot Hiring

No open roles listed right now. Follow ALX Oncology to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ALX2004

Non-small Cell Lung Cancer

Phase 1

Clinical Trials (1)

NCT07085091A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

Phase 1

Help build intelligence for ALX Oncology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage immuno-oncology focus positions you at the forefront of a high-growth therapeutic area with significant unmet need in solid tumors
Opportunity to shape development strategy for novel immunotherapy mechanisms before major clinical inflection points
South SF location provides access to biotech talent ecosystem and proximity to leading cancer research centers

Watch Out For

No approved products or clinical revenue; company is entirely dependent on successful advancement of early-stage pipeline (evorpacept in Phase 1/2, ALX2004 in Phase 1)
Currently zero open job postings indicates potential hiring freeze, possible financial constraints, or organizational restructuring
Missing data on funding, employee count, and financial trajectory creates visibility gaps on runway and stability

Generated by Claude from ALX Oncology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

evorpacept

Advanced Solid Tumors

Phase 1/2

Clinical Trials (5)

NCT07007559ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Phase 2

NCT05524545A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

Phase 1

NCT04417517A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

Phase 1

+2 more

Pembrolizumab

Ovarian Cancer

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 6 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

6 pipeline

Marketed

Pipeline